Mechanisms of HIV-Related Lung Disease (U01)

Post Date

December 14th 2012

Application Due Date

March 19th 2013

Funding Opportunity Number

RFA-HL-13-026

CFDA Number(s)

93.838

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Award Range:

  $None - $440000

Grant Description

The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to investigate and define cellular and molecular events, including host genetic factors, underlying the pathogenesis of HIV-associated lung diseases (e.g., COPD and pulmonary hypertension). Biospecimens and clinical data from HIV-infected patients and controls should be utilized. Clinical translation is encouraged to the extent that it is possible. Both independent (site-specific) and collaborative research with other groups funded by this FOA will be conducted under this program. The goals are to identify disease sub-phenotypes, potential biomarkers to predict risk, progression, and outcome, and molecular targets to help design therapeutic interventions.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-13-026.html